Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0M4MH
|
|||
| Former ID |
DIB000809
|
|||
| Drug Name |
ATR-107
|
|||
| Synonyms |
PF-05230900
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Crohn disease [ICD-11: DD70; ICD-10: K50, K50.9; ICD-9: 555] | Phase 1 | [1] | |
| Company |
Wyeth
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Interleukin 21 receptor (IL21R) | Target Info | . | [1] |
| KEGG Pathway | Cytokine-cytokine receptor interaction | |||
| Jak-STAT signaling pathway | ||||
| Inflammatory bowel disease (IBD) | ||||
| NetPath Pathway | TCR Signaling Pathway | |||
| IL2 Signaling Pathway | ||||
| IL5 Signaling Pathway | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Anti-IL21 receptor monoclonal antibody (ATR-107): Safety, pharmacokinetics, and pharmacodynamic evaluation in healthy volunteers: a phase I, first-in-human study. J Clin Pharmacol. 2014 Jan;54(1):14-22. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.